Andrew Bryson1, Paul E Jennings2, Laszlo Deak3, Fraga S Paveliu4, Matt Lawson1. 1. a Clinical Department , Mitsubishi Tanabe Pharma Europe Ltd , London , UK. 2. b Center for Diabetes and Endocrinology , York Teaching Hospital NHS Foundation Trust Ringgold , York , UK. 3. c Department of Internal Medicine , Kaposi Mor County Hospital , Kaposvar , Hungary. 4. d Department of Nutrition and Endocrinology , Societatea Civila Medicala , Bucharest , Romania.
Abstract
OBJECTIVE: The study investigated the efficacy and tolerability of teneligliptin co-administered to patients with type 2 diabetes mellitus (T2DM) who were inadequately controlled by stable metformin monotherapy ≥ 1000 mg/day. METHODS: A total of 447 patients from 55 European centers who completed a 14-day screening and 14-day run-in phase, received randomized double-blind treatment with 5, 10, 20 or 40 mg teneligliptin or placebo once daily, for 24 weeks. 364 patients continued treatment in a 28-week open label extension during which they receivedteneligliptin 20 mg once daily. RESULTS: Co-administration of teneligliptin (5 to 40 mg) with metformin demonstrated dose-related and statistically significant reductions in HbA1c after 24 weeks (-0.30 to -0.63% placebo adjusted) of double-blind treatment. The greatest reduction in HbA1c was seen with teneligliptin at 40 mg (-0.63%) at Week 24. There was also a dose-dependent increase in proportion of responders achieving HbA1c < 7.0% at this endpoint. Responses were maintained throughout 28 weeks open label treatment with 20 mg teneligliptin. Treatment was well tolerated to Week 52 and the overall incidence of hypoglycemia during 52 weeks was 2.3%. CONCLUSIONS:Teneligliptin co-administered with metformin produced significant reductions in HbA1c in patients with T2DM without increasing the risk of hypoglycemia.
RCT Entities:
OBJECTIVE: The study investigated the efficacy and tolerability of teneligliptin co-administered to patients with type 2 diabetes mellitus (T2DM) who were inadequately controlled by stable metformin monotherapy ≥ 1000 mg/day. METHODS: A total of 447 patients from 55 European centers who completed a 14-day screening and 14-day run-in phase, received randomized double-blind treatment with 5, 10, 20 or 40 mg teneligliptin or placebo once daily, for 24 weeks. 364 patients continued treatment in a 28-week open label extension during which they received teneligliptin 20 mg once daily. RESULTS: Co-administration of teneligliptin (5 to 40 mg) with metformin demonstrated dose-related and statistically significant reductions in HbA1c after 24 weeks (-0.30 to -0.63% placebo adjusted) of double-blind treatment. The greatest reduction in HbA1c was seen with teneligliptin at 40 mg (-0.63%) at Week 24. There was also a dose-dependent increase in proportion of responders achieving HbA1c < 7.0% at this endpoint. Responses were maintained throughout 28 weeks open label treatment with 20 mg teneligliptin. Treatment was well tolerated to Week 52 and the overall incidence of hypoglycemia during 52 weeks was 2.3%. CONCLUSIONS:Teneligliptin co-administered with metformin produced significant reductions in HbA1c in patients with T2DM without increasing the risk of hypoglycemia.
Entities:
Keywords:
Co-administration; diabetes mellitus; metformin; teneligliptin; type 2
Authors: Sanaz Kamalinia; Robert G Josse; Patrick J Donio; Lindsay Leduc; Baiju R Shah; Sheldon W Tobe Journal: Endocrinol Diabetes Metab Date: 2019-11-13
Authors: Ashok K Das; Pramod Gandhi; Banshi Saboo; Sanjay Reddy; Rajeev Chawla; Abdul Hamid Zargar; Rajiv Kovil; Manoj Chawla; S K Sharma; Sunil Gupta; B M Makkar; Vinod Mittal; Soumik Goswami; S R Arvind; Shalini Jaggi; Sarita Bajaj; Sambit Das Journal: J Family Med Prim Care Date: 2021-12-27